Public

US Securities Class Action

Anavex Life Sciences Corp

Between November 26, 2025 and August 28, 2026, Anavex Life Sciences told investors its disclosure controls and internal controls over financial reporting were effective. Executives also described regulatory approval risks while pursuing development of blarcamesine and other drug candidates.

However, during this period, investors allege former CEO Christopher Missling’s conduct created deficiencies in internal controls and made regulatory compliance more difficult. Anavex Life Sciences allegedly failed to disclose Its internal controls were inadequate its former CEO did not prioritize regulatory and clinical compliance and took steps that discouraged those efforts and its regulatory challenges were greater because important regulatory, clinical, and other information was not consistently shared with the Board and other decision-makers.

Then, on May 6, 2026, Anavex Life Sciences revealed that Missling had been terminated for cause for conduct the Board’s special committee believed violated company policy. On May 12, $AVXL fell 5.55%, closing at $3.06, after the company delayed a quarterly filing while reviewing matters related to his termination. 

Additional disclosures in August revealed a material weakness in internal controls, ineffective disclosure controls, gaps in sharing regulatory and clinical information, and paused development of several drug candidates. $AVXL fell 6.35% on August 31, closing at $2.80.

Based on these events, $AVXL investors filed a claim against Anavex Life Sciences, alleging the company:

Investors argue Anavex Life Sciences misled the market about its internal controls and regulatory compliance processes, causing losses when the truth emerged.

Lead Plaintiff Submission

Mismanagement

Anavex Life Sciences ($AVXL) Internal Controls and Regulatory Compliance Case